Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-812 in children with ADHD
NCT02633527Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Feb 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of viloxazine in attention deficit hyperactivity disorder (ADHD), sponsored by Supernus Pharmaceuticals, Inc.. Started Feb 2016; status: completed.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02633527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633527.